New Key Statistics Module, Z-Score and F-Score
OTCPK:LTPCF Key Ratios
| Market Cap $ M | -- |
| Enterprise Value $ M | -- |
| P/E(ttm) | 17.60 |
| PE Ratio without NRI | 17.60 |
| Forward PE Ratio | 12.39 |
| Price/Book | 3.85 |
| Price/Sales | 4.17 |
| Price/Free Cash Flow | 28.74 |
| Price/Owner Earnings | 35.86 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -- |
| Beneish M-Score | -2.34 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 44.10 |
| y-y EBITDA Growth Rate % | -8.90 |
| EV-to-EBIT | 14.04 |
| EV-to-EBITDA | 11.50 |
| PEG | 0.40 |
| Shares Outstanding M | 238.49 |
| Net Margin (%) | 23.70 |
| Operating Margin % | 26.65 |
| Pre-tax Margin (%) | 29.77 |
| Quick Ratio | 1.58 |
| Current Ratio | 2.16 |
| ROA % (ttm) | 12.05 |
| ROE % (ttm) | 23.56 |
| ROIC % (ttm) | 13.00 |
| Dividend Yield % | -- |
| Altman Z-Score | 4.34 |
LTPCF Number of Guru Trades
LTPCF Volume of Guru Trades
Gurus Latest Trades with OTCPK:LTPCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:LTPCF is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Lotus Pharmaceutical Co Ltd Insider Transactions
No Available Data
News about OTCPK:LTPCF
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers